$34 M

BLGO Mkt cap, 08-Oct-2018

$364 K

BioLargo Revenue Q1, 2019
BioLargo Net income (Q1, 2019)-2.7 M
BioLargo EBIT (Q1, 2019)-1.7 M
BioLargo Cash, 31-Mar-2019512 K
BioLargo EV36.4 M

BioLargo Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

167.9k111.5k281.1k516.2k1.4m

Revenue growth, %

(34%)

Cost of goods sold

29.7k56.0k62.1k105.9k743.0k

Gross profit

138.3k55.5k175.2k621.0k

Gross profit Margin, %

82%50%62%46%

R&D expense

742.2k642.9k684.6k1.4m1.6m1.7m

General and administrative expense

2.0m2.8m3.6m3.7m4.4m5.3m

Operating expense total

2.8m3.4m4.2m5.1m6.1m7.0m

Depreciation and amortization

13.7k29.8k50.0k

EBIT

(2.6m)(3.4m)(4.2m)(4.9m)(5.9m)(6.4m)

EBIT margin, %

(1560%)(3040%)(1756%)(1142%)(470%)

Interest expense

281.6k348.2k994.7k3.1m3.9m3.5m

Net Income

(2.9m)(3.7m)(5.1m)(8.1m)(9.5m)(10.7m)

BioLargo Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

92.4k154.5k1.8m1.9m990.5k655.0k

Accounts Receivable

41.4k68.0k

Inventories

29.8k25.5k37.4k34.4k54.0k

Current Assets

126.2k230.6k1.9m2.0m1.2m955.0k

PP&E

108.9k126.0k

Total Assets

167.2k260.7k1.9m2.1m1.5m3.2m

Accounts Payable

407.2k494.9k135.0k13.7k224.1k501.0k

Short-term debt

325.0k250.0k1.8m

Current Liabilities

732.2k652.9k460.0k1.2m4.2m2.5m

Long-term debt

250.0k3.2m560.0k5.2m400.0k

Non-Current Liabilities

309.0k

Total Debt

325.0k500.0k3.2m560.0k5.2m2.2m

Total Liabilities

732.2k768.9k2.9m4.9m4.3m

Additional Paid-in Capital

74.8m78.5m84.4m90.6m97.1m110.2m

Retained Earnings

(75.3m)(79.0m)(84.1m)(91.9m)(101.2m)(111.7m)

Total Equity

1.1m(770.2k)(3.4m)(1.1m)

Debt to Equity Ratio

-0.7 x-1.5 x

Debt to Assets Ratio

1.9 x0.3 x3.5 x

Financial Leverage

1.7 x-2.7 x-0.4 x-2.8 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

363.4k318.3k151.7k227.4k96.9k560.2k1.0m889.0k1.7m1.2m433.5k1.3m921.9k651.1k533.5k512.0k

Accounts Receivable

7.6k38.4k27.0k46.7k83.3k78.1k113.6k210.0k

Inventories

33.7k24.7k62.7k20.5k14.6k12.7k32.0k23.9k25.6k24.6k36.9k39.3k56.8k25.6k46.2k

Current Assets

446.5k391.0k264.0k300.4k164.1k666.7k1.2m1.0m1.9m1.4m561.3k1.4m1.1m823.3k752.3k782.0k

PP&E

5.4k55.0k54.1k50.3k55.2k117.3k110.0k

Total Assets

484.7k426.5k296.9k383.2k264.1k767.7k1.2m1.0m2.0m1.5m643.0k1.7m1.5m1.2m1.1m3.4m

Accounts Payable

358.7k331.3k420.9k150.0k444.0k125.0k100.0k100.0k236.7k344.4k455.5k351.0k254.7k361.1k631.0k

Short-term debt

50.0k50.0k50.0k330.0k4.9m4.9m5.8m1.2m2.5m

Current Liabilities

508.7k481.3k622.6k791.2k709.6k400.6k357.5k411.1k831.2k696.8k3.7m3.6m5.1m943.5k1.8m3.1m

Long-term debt

283.0k250.0k3.5m50.0k280.0k4.8m4.8m5.4m782.2k490.0k

Non-Current Liabilities

5.6k39.7k109.9k2.1m

Total Debt

50.0k50.0k50.0k283.0k250.0k3.5m50.0k610.0k9.7m50.0k11.2m2.0m3.0m

Total Liabilities

508.7k481.3k622.6k749.3k510.6k972.6k1.5m2.1m3.1m4.1m4.1m6.1m1.8m2.1m5.2m

Additional Paid-in Capital

76.4m77.3m77.8m79.3m80.4m83.0m85.1m86.2m88.9m91.8m92.5m95.8m98.6m106.2m108.2m112.6m

Retained Earnings

(76.3m)(77.4m)(78.3m)(79.8m)(81.0m)(82.8m)(85.7m)(87.3m)(89.7m)(93.9m)(96.3m)(98.9m)(103.8m)(107.3m)(109.6m)(114.6m)

Total Equity

(485.2k)257.2k217.6k(428.3k)(160.1k)(1.6m)(3.5m)(2.4m)(4.6m)(644.5k)(980.9k)(1.8m)

Debt to Equity Ratio

-0.3 x0 x-3 x

Debt to Assets Ratio

0 x0 x1.7 x

Financial Leverage

-0.5 x3 x5.5 x-2.4 x-12.3 x-0.9 x-0.2 x-0.7 x-0.3 x-1.8 x-1.1 x-1.9 x

BioLargo Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(2.9m)(3.7m)(5.1m)(8.1m)(9.5m)(10.7m)

Depreciation and Amortization

13.7k

Accounts Receivable

7.7k(1.7k)(35.8k)(26.6k)(28.9k)(163.0k)

Inventories

24.2k4.3k(11.9k)3.0k(19.5k)28.0k

Accounts Payable

132.2k139.3k(110.6k)(124.9k)114.4k284.0k

Cash From Operating Activities

(1.2m)(1.7m)(1.9m)(3.7m)(4.3m)(3.9m)

Cash From Investing Activities

(61.9k)(28.7k)(58.0k)

Cash From Financing Activities

1.2m1.8m3.5m4.0m3.4m3.6m

Interest Paid

6.7k9.9k8.7k54.0k

Income Taxes Paid

2.8k7.7k5.4k13.0k

BioLargo Ratios

USDY, 2019

EV/EBIT

-21.9 x

EV/CFO

-41.9 x

Financial Leverage

-1.9 x